



Sebastian F. Schoppmann

TABLE OF CONTENTS

1. Short Biography
2. Curriculum vitae (i) (including summary of previous research and teaching activities (iii), the ten best publications from the point of view of the applicant download option (see separate form)
3. Scientific Cooperations and Bibliography (ii)
4. Teaching (iii)
5. Third-Party Funding

1. SHORT BIOGRAPHY

Personal data	
Sebastian F. Schoppmann, MD, Associate Professor of Surgery	
Born July 14, 1975, married, 4 children	
University training	
Human medicine, completed on Oct. 12, 2000; dissertation: "Lymphatic microvessels in invasive breast cancer – a prognostic factor?" (supervisor: D. Kerjaschki)	
Current positions	
Second Deputy Chief, Div. of General Surgery, Dept. of Surgery (DoS), Medical University of Vienna (MUV)	
Chair, Surgical Functional Diagnostics, MUV DoS	
Chair, Task Force on Gastroesophageal Surgery, Div. of General Surgery, MUV DoS	
Chair, Special Clinic for Gastroesophageal Disorders, Div. of General Surgery, MUV DoS	
Chair, Reflux Clinic, Div. of General Surgery, MUV DoS	
Coordinator, Gastroesophageal Tumor (GET) Unit, MUV Comprehensive Cancer Center (CCC) Vienna	
Co-coordinator, MUV CCC Platform for Molecular Diagnostics and Treatment in Oncology	
Visiting Professor, DoS, Univ. of Milan (until December 31, 2019)	
Professional knowledge and training	
Habilitation (venia docendi) in surgery: "Mechanisms of lymphatic metastasization in human carcinoma and their clinical relevance" (in German)	
Additional specialization in vascular surgery, 2018	
Subspecialization in surgical intensive care medicine, 2017	
Subspecialization in visceral surgery, 2009	
Specialist in General Surgery, since 2007	
Publications (Google Scholar, ISI Web)	
Peer-reviewed publications: total	187
Peer-reviewed publications: first/last authorships	104
Peer-reviewed publications: total IF	IF 873.3
Peer-reviewed publications: total citations	6109
Peer-reviewed publications: IF as first/last author	IF 434.4
Peer-reviewed publications: citations as first/last author	3483
Book chapters	7
Original articles in peer-reviewed journals	126
Original articles in peer-reviewed journals: IF	IF 465.1
Original articles in peer-reviewed journals: citations	5931
Original articles in peer-reviewed journals: first/last authorships	62
Original articles in peer-reviewed journals: IF as first/last author	IF 256.4
Original articles in peer-reviewed journals: citations as first/last author	3321
Total IF: 873.3 Total citations: 6109 h-index: 35 i10-index: 81	

List of the ten most important publications: [Publikationen Schoppmann Download](#)

International (extramural) experience

Postdoc fellowship, Research Inst. of Molecular Pathology (IMP) Vienna, Austria

Consultant in Epigastric Surgery, Medical Univ. of Vienna International (MUVI), Prince Court Medical Centre, Kuala Lumpur, Malaysia

Visiting professor, DoS, Keck School of Medicine of USC, Los Angeles, USA

Visiting professor, DoS, Univ. of Milan, Milan, Italy

Total volume of revenues from competitive institutions and the industry

> € 800,000

Journal editorships

Section Editor, European Surgery; Associate Editor, European Journal of Surgical Oncology (until 2012); Consulting Editor (select), Annals of Surgical Oncology, Journal of Leucocyte Biology, Acta Biologica Hungarica, British Journal of Cancer, British Journal of Surgery, Oncology, German Research Foundation, British Journal of Oncology, BMC Cancer, Cell and Molecular Life Science, World Journal of Surgical Oncology, Breast Care, European Journal of Surgical Oncology, Journal of Cellular and Molecular Biology

Reviewer, German Research Foundation

Teaching and guidelines

Regular courses at the MUV

Guidelines on the treatment of esophageal and gastric tumors, Austrian Society of Surgical Oncology (ACO-ASSO)

Personal supervision for several degree, doctoral and habilitation projects

Teaching documents in cancer surgery (Lehrunterlage Block 13 Krebschirurgie; 2018)

Courses on esophageal cancer and acid reflux, MUV CCC Cancer School

Head of Clinical Teaching, MUV Task Force on Teaching

Head of Strategy, MUV Task Force on Training

National and international extramural activities/awards

Postdoc Research Fellow, IMP Vienna, Austria

Fellow, MUVI Consultant in Epigastric Surgery, Prince Court Medical Centre, Kuala Lumpur, Malaysia

Visiting Professor, DoS, Keck School of Medicine of USC, Los Angeles, USA

Visiting Professor, DoS, Univ. of Milan, Milan, Italy

Advisory Committee Member, European Society of Surgical Oncology (ESSO) Membership

Secretary, American College of Surgeons (ACS) – Austrian/Hungarian Chapter

Scientific Committee Permanent Member, World Organization for Specialized Studies on Diseases of the Esophagus (OESO)

Local Chair, International Congress of the International Society for Diseases of the Esophagus (ISDE)

Founding Member, American Foregut Society (AFS)

Secretary General, ACO-ASSO

President of the Austrian Society of Surgical Oncology

Secretary General, Austrian Society for Robotic Surgery (ÖGR)

Chair, Austrian Society of Esophageal Surgery (ÖGÖ)

Panel Member, Gastrointestinal Stromal Tumor (GIST) Panel Austria

2. CURRICULUM VITAE

2.1 Personal information	
Name	Sebastian Friedrich Schoppmann, MD, FACS
Date of birth	July 14, 1975 (age: 43 years)
Place of birth	Mainz, German
Nationality	Germany
Family status	Married, Alexandra Schoppmann, MD 4 children (Paul 8, Jan 6, Lukas, 4, Sophie 2)
Home address	Josef Brenner Strasse 11A, Klosterneuburg A-3400, Austria

2.2 Education	
Oct. 12, 2000	Doctor of Medicine, dissertation: "Lymphatic microvessels in invasive breast cancer" (supervisor: D. Kerjaschki)
Feb. 1, 1997 – Oct. 31, 2000	Research Associate, Div. of Ultrastructural Pathology, Inst. of Clinical Pathology, Univ. of Vienna, Vienna, Austria
1994 – 2000	Medical studies, Univ. of Vienna
1986 – 1994	Klosterneuburg High School, Klosterneuburg, Austria
1980 – 1986	Grade schools in the USA, Germany and Austria

2.3 Postgraduate training	
2018	Additional specialization in vascular surgery
2017	Subspecialization in surgical intensive care medicine
2009	Subspecialization in visceral surgery
Dec. 14, 2007	Appointed Specialist in General Surgery
Mar. 1, 2007	Conferred the degree of Associate Professor
2006	Conferred the Venia Docendi in Surgery, Medical University of Vienna (MUV) ("Mechanisms of lymphatic metastasization in human carcinoma and their clinical relevance" (in German)
2006	Specialist training, Dept. of General and Vascular Surgery, St. Pölten Hospital (clinical rotation)
Jan. 2002 – 2007	Specialist training in General Surgery, Div. of General Surgery, Dept. of Surgery (DoS), MUV
Apr. 2001 – Jan. 2002	Specialist training in clinical pathology, Inst. of Clinical Pathology, MUV
Jan. – Jul. 2001	Postdoctoral position, Research Inst. for Molecular Pathology (IMP), MUV,
Nov. 2000 – Mar. 2001	Research associate, Austrian Science Fund (FWF) Special Research Program (SFB), Fund of the Inst. of Vascular Biology and Thrombosis Research

2.4 Professional career	
2019 –	Visiting Professor, DoS, Univ. of Milan, San Donato Hospital, Milan, Italy (L. Bonavina)
2019 –	Second Deputy Chief, Div. of General Surgery, MUV DoS
2018	Visiting professor, DoS, Keck School of Medicine of USC, Los Angeles, USA (J. Lipham)
2016 – 2018	Deputy Chief, Div. of General Surgery, MUV DoS
2016	Appointed Fellow of the American College of Surgeons (FACS)
2013 –	Coordinator, MUV Comprehensive Cancer Center (CCC) Gastroesophageal Tumor (GET) Unit
2013 –	Head, Gastro – Esophagus – Gastrointestinal Stromal Tumor (GIST) Tumor Board, MUV CCC

2012 –	Head, Gastroesophageal Surgery Task Force, Div. of General Surgery, MUV DoS
2012 –	Chief Attending Physician, Div. of General Surgery, MUV DoS
2010 –	Principal Investigator, Upper GI Research Laboratory, Surgical Research Laboratories, MUV DoS
2009 –	Attending Physician, Div. of General Surgery, MUV DoS
Sep. 2008 – Feb. 2009	Fellow – Consultant in Epigastric Surgery, Prince Court Medical Centre, Kuala Lumpur, Malaysia, MUVI
Dec. 14, 2007	Appointed specialist in general surgery
Jan. 2002 – 2007	Specialist training in general surgery
Apr. 2001 – Jan. 2002	Specialist training, Inst. of Clinical Pathology, MUV

2.5 Intramural organizational and leadership tasks

2018	Member, MUV Task Force: Support for Young Researchers
2018	Head of Clinical Teaching, MUV Task Force on Teaching
2017 –	Head of Strategy, Task Force on Training, MUV / Vienna General Hospital
2017 –	Training Officer, MUV DoS
2012 – 2018	Head, Human Resource Management, Div. of General Surgery, MUV DoS

2.6 Leadership functions in national and international societies

2018 –	President, Austrian Society of Esophageal Surgery (ÖGÖ)
2018 –	Secretary General, Austrian Society of Robotic Surgery (ÖGR)
2018	Founding Member, American Foregut Society (AFS)
2018 –	Member, European Society of Surgical Oncology (ESSO) Membership Advisory Committee
2018 –	President Austrian Society of Surgical Oncology (ACO-ASSO) 2019-2021
2017 –	Scientific Committee Permanent Member, World Organization for Specialized Studies on Diseases of the Esophagus (OESO)
2017 –	Secretary, Central and Eastern European Association for the Study of Barrett's Esophagus (CEABE)
2017 –	Secretary General, Association for the Promotion of Science and Research in the New Univ. Clinics at the General Hospital of the City of Vienna (vfwf)
2017 –	Secretary, ACS Austrian/Hungarian Chapter
2014 –	Secretary General, ACO-ASSO
2013 –	Board Member, GIST Panel Austria
2010 –	Board Member, ACO-ASSO
2009 – 2011	Curriculum Director, Vienna Office of the European Society of Quality in Healthcare (ESQH)

2.7 Leadership functions in national and international medical events (Selection)

2019	Invited Faculty, 11 th International EFR – European Federation for coloRectal Cancer – Congress, Vienna, Austria
2019	Member, Scientific Committee of the 13 th International Gastric Cancer Congress (IGCC), Prague, Czech Republic
2018	Local Chair, International Congress of the International Society for Diseases of the Esophagus (ISDE), Vienna
2018	Co-Chair (with M Preusser), Update CCC-GET on the Treatment of Gastric and Esophageal Tumors
2016	Co-Chair (with M Raderer, B Niederle), CCC-Update Rare Tumors (GIST / Neuroendocrine Tumors [NET])
2015	Chair, Multidisciplinary Reflux Meeting, Upper GI Research and Service (Van Swieten)
2014 –	Chair, Basic & Advanced Workshops in Minimally Invasive Surgery, CCC-GET (laparoscopic techniques in the porcine model; quarterly workshops)
2014	President, 31 th ACO-ASSO Annual Meeting (“Multimodal Personalized Tumor Therapy”)
2014	Scientific Committee, 24 th World Congress of the International Associations of Surgeons, Gastroenterologists and Oncologists

2013 –	Coordinator, numerous international events of the CCC-GET Unit Vienna
2011	Organizing Committee, Task Force on Gastric Tumors & Austrian Breast & Colorectal Cancer Study Group Annual Conference – Gastrointestinal Tumors
2010	Conference Secretary, 27 th ACO-ASSO Annual Conference, “GIST – Gastrointestinal Stromal Tumors”
2009	Conference Secretary, 26 th ACO-ASSO Annual Conference, “Individualized Cancer Treatments”

2.8 Awards	
2007	Theodor Billroth Prize, Austrian Society of Surgery (ÖGC; co-author)
2007	ACO-ASSO Prize, ACO-ASSO (first author)
2004	Promotion Award, City of Vienna Fund for Innovative Interdisciplinary Cancer Research (first author)
2003	Theodor Billroth Prize, Vienna Medical Chamber (first author)

3. SCIENTIFIC COOPERATION AND BIBLIOGRAPHY

3.1 Clinical and scientific cooperation partners (select)
DoS, Keck School of Medicine of USC, Los Angeles, California, USA
Foundation for Research and Education in Esophageal and Foregut Disease, Chicago, Illinois, USA
DoS, Univ. of Milan, San Donato Hospital, Milan, Italy
Univ. Hospital for Digestive Disease (Surgery???), Univ. of Belgrade, Belgrade, Serbia
General and Abdominal Surgery, Schön Clinic Nürnberg Fürth, Germany
Medical Department, Diakonie Klinikum Jung-Stilling, Siegen, Germany
Centre for Integrated Healthcare Research, Durham Univ., Durham, UK
Metabolic Epidemiology Branch, Div. of Cancer Epidemiology and Genetics, National Cancer Inst., NIH, DHHS, Bethesda, USA
Dept. of Dermatology, Univ. Hospital Zurich, Univ. of Zurich, Switzerland
DoS, Medical Univ. of Innsbruck, Innsbruck, Austria
Dept.s of General Surgery and Visceral Surgery, Ordensklinikum Linz, Linz, Austria
St. Josef Hospital, Vienna, Austria
Klagenfurt Clinic, Klagenfurt, Austria
MUV First Medical Dept., Vienna, Austria
MUV Fourth Medical Dept., Vienna, Austria
MUV Dept. of Radiology and Nuclear Medicine, Vienna, Austria
MUV Center for Biomedical Research, Vienna, Austria
MUV Inst. for Cancer Research, Vienna, Austria
MUV Dept. of Otorhinolaryngology, Head and Neck Surgery, Vienna, Austria
MUV Dept. of Anesthesiology, General Intensive Care and Pain Management, Vienna, Austria
Zhongshan Hospital, Fudan Univ., Shanghai, China
Wilheminspital, Vienna, Austria
Sozialmedizinisches Zentrum Nord, Vienna, Austria
Dept. of General and Visceral Surgery, Brothers of Mercy Hospital Regensburg, Regensburg, Germany
Health Transformation Building, Univ. of Texas at Austin, Austin, Texas, USA
Inst. of Pathology, Univ. of Heidelberg, Heidelberg, Germany
Dept. of Visceral, Transplant, Thoracic and Vascular Surgery, Leipzig Univ. Hospital, Leipzig, Germany
DoS, Univ. of Lübeck, Lübeck, Germany
Cantonal Hospital of Winterthur, Winterthur, Switzerland (Bern, Schweiz Bern Adamina???)
DoS, Univ. Hospital of Bern, Bern, Switzerland
Hirslanden Klinik Beau-Site, Bern, Switzerland
Div. of Gastroenterology and Hepatology, Mayo Clinic, Phoenix, Arizona, USA
MUV Inst. of Clinical Pathology, Vienna, Austria
Dept. of Pathology, Charles University Faculty of Medicine in Pilsen, Pilsen, Czech Republic

Harvard Skin Disease Research Center, Dept. of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA

Creighton Univ. School of Medicine, Omaha, Nebraska, USA

3.2 Summary of publications (Google Scholar, ISI Web)

Total of publications	194
Peer-reviewed publications: total	187
Peer-reviewed publications: first/last authorships	104
Peer-reviewed publications: total IF	IF 875.3
Peer-reviewed publications: total citations	6109
Peer-reviewed publications: IF as first/last author	IF 434.4
Peer-reviewed publications: citations as first/last author	3483
Book chapters	7
Original articles in peer-reviewed journals	126
Original articles in peer-reviewed journals: IF	IF 465.4
Original articles in peer-reviewed journals: citations	6109
Original articles in peer-reviewed journals: first/last authorships	62
Original articles in peer-reviewed journals: IF as first/last author	IF 256.4
Original articles in peer-reviewed journals: citations as first/last author	3321
H-Index	35

3.3 Bibliography

3.3.1 Original articles published in peer-reviewed journals (IF taken from Journal Citation Reports, Thomson Reuters 2017)

1. Nikolic M, Schwameis K, Kristo I, Paireder M, Matic A, Semmler G, Semmler L, Schoppmann SF. **Ineffective Esophageal Motility in Patients with GERD is no Contraindication for Nissen Fundoplication** World J Surg 2019 Oct 11. doi: 10.1007/s00268-019-05229-y. IF 2.768
2. Jomrich G, Hudec X, Harpain F, Winkler D, Timelthaler G, Mohr T, Marian B, Schoppmann SF. **Expression of FGF8, FGF18 and FGFR4 in Gastroesophageal Adenocarcinomas** Cells 2019 Sep 16;8(9). pii: E1092. doi: 10.3390/cells8091092. IF 5.656
3. Kristo I, Paireder M, Jomrich G, Felsenreich DM, Nikolic M, Langer FB, Prager G, Schoppmann SF. **Modern esophageal function testing and gastroesophageal reflux disease in morbidly-obese patients.** Obes Surg 2019, Jun 14. doi: 10.1007/s11695-019-04020-1. IF 3.895
4. Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Schoppmann SF. **High systemic immune-inflammation index is an adverse prognostic factor for patients with gastroesophageal adenocarcinoma.** Ann Surg 2019, Aug 16. doi: 10.1097/SLA.0000000000003370 IF 9.203, cited 1 time.

5. Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, [Schoppmann SF](#).
High mean corpuscular volume predicts poor outcome for patients with gastroesophageal adenocarcinoma
Annals of Surgical Oncology 2019, 26 (4), pp. 976-985
IF 3.857, cited 1 time.
6. Nikolic M, Schwameis K, Semmler G, Asari R, Semmler L, Steindl A, Mosleh BO, [Schoppmann SF](#).
Persistent dysphagia is a rare problem after laparoscopic Nissen fundoplication
Surgical Endoscopy 2019, 33 (4), pp. 1196-1205
IF 3.117
7. Paireder M, Kristo I, Asari R, Jomrich G, Steindl J, Rieder E, [Schoppmann SF](#).
Electrical lower esophageal sphincter augmentation in patients with GERD and severe ineffective esophageal motility—a safety and efficacy study
Surgical Endoscopy 2019, in press.
IF 3.117
8. Tamandl D, Fueger B, Haug A, Schmid R, Stift J, [Schoppmann SF](#), Ilhan-Mutlu A, Ba-Ssalamah A.
A diagnostic algorithm that combines quantitative 18 F-FDG PET parameters and contrast-enhanced CT improves posttherapeutic locoregional restaging and prognostication of survival in patients with esophageal cancer
Clinical Nuclear Medicine 2019, 44 (1), pp. e13-e21.
IF 6.309
9. Paireder M, Asari R, Kristo I, Rieder E, Zacherl J, Kabon B, Fleischmann E, [Schoppmann SF](#).
Morbidity in open versus minimally invasive hybrid esophagectomy (MIOMIE): Long-term results of a randomized controlled clinical study
European Surgery - Acta Chirurgica Austriaca 2018, 50 (6), pp. 249-255.
IF 0.349, cited 1 time.
10. Kristo I, Schwameis K, Maschke S, Kainz A, Rieder E, Paireder M, Jomrich G, [Schoppmann SF](#).
Phenotypes of Jackhammer esophagus in patients with typical symptoms of gastroesophageal reflux disease responsive to proton pump inhibitors
Scientific Reports 2018, 8 (1), art. no. 9949,
IF 4.122
11. Schwameis K, Nikolic M, Castellano DGM, Steindl A, Macheck S, Riegler M, Kristo I, Zörner B, [Schoppmann SF](#).
Crural closure improves outcomes of magnetic sphincter augmentation in GERD patients with hiatal hernia
Scientific Reports 2018, 8 (1), art. no. 7433,
IF 4.122, cited 3 times.
12. Schwameis K, Nikolic M, Morales Castellano DG, Steindl A, Macheck S, Kristo I, Zörner B, [Schoppmann SF](#).
Results of Magnetic Sphincter Augmentation for Gastroesophageal Reflux Disease
World Journal of Surgery 2018, 42 (10), pp. 3263-3269.
IF 2.766, cited 3 time.
13. Rieder E, Paireder M, Kristo I, Schwameis K, [Schoppmann SF](#).
Electrical Stimulation of the Lower Esophageal Sphincter to Treat Gastroesophageal Reflux After POEM
Surgical Innovation 2018, 25 (4), pp. 346-349.
IF 1.549
14. Kappel-Latif S, Zacherl J, Hejna M, Westerhoff M, Tamandl D, Ba-Ssalamah A, Mittlböck M, Wolf B, Wrba F, Kührer I, Pluschnig U, [Schoppmann SF](#), Függer R, Zwrtek R, Glaser K, Karner J, Längle F, Wenzl E, Roka R, Öfner D, Tschmelitsch J, Hold M, Keil F, Gnant M, Kandioler D, Kandioler D, the Pancho trialists and for the Medical University of Vienna p53 research group
Pancho trial (p53-adapted neoadjuvant chemotherapy for resectable esophageal cancer) completed—mutation rate of the marker higher than expected
European Surgery - Acta Chirurgica Austriaca 2018, 50 (4), pp. 160-166.
IF 0.349, cited 2 times.
15. Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Baierl A, Kazakov D, Michal M, French LE, Hoetzenecker W, Schatton T, Asari R, Preusser M, Gnant M, Guenova E, [Schoppmann SF](#).
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Oncoimmunology 2018, 7 (6), art. no. e1435226,
IF 5.503, cited 4 times.

16. Kristo I, Schwameis K, Paireder M, Jomrich G, Kainz A, [Schoppmann SF](#).
Dysphagia severity is related to the amplitude of distal contractile integral in patients with Jackhammer esophagus
Neurogastroenterology and Motility 2018, 30 (5), art. no. e13276,
IF 3.842, cited 2 time.
17. Ilhan-Mutlu, A., Taghizadeh, H., Beer, A., Dolak, W., Ba-Ssalamah, A., [Schoppmann, S.F.](#), Hejna, M., Birner, P., Preusser, M.
Correlation of trastuzumab-based treatment with clinical characteristics and prognosis in HER2-positive gastric and gastroesophageal junction cancer: A retrospective single center analysis
Cancer Biology and Therapy 2018, 19 (3), pp. 169-174.
IF 3.373, cited 1 time.
18. Kristo I, Rieder E, Paireder M, Schwameis K, Jomrich G, Dolak W, Parzefall T, Riegler M, Asari R, [Schoppmann SF](#).
Radiofrequency ablation in patients with large cervical heterotopic gastric mucosa and globus sensation: Closing the treatment gap
Digestive Endoscopy 2018, 30 (2), pp. 212-218.
IF 3.375, cited 2 times.
19. Arnoldner MA, Kristo I, Paireder M, Cosentini EP, Schima W, Weber M, [Schoppmann SF](#), Kulinna-Cosentini C.
Swallowing MRI—a reliable method for the evaluation of the postoperative gastroesophageal situs after Nissen fundoplication
European Radiology 2018, Nov 2018, Epub ahead of print
IF 4.027, cited 1 time.
20. Jomrich G, Maroske F, Stieger J, Preusser M, Ilhan-Mutlu A, Winkler D, Kristo I, Paireder M, [Schoppmann SF](#).
MK2 and ETV1 are prognostic factors in esophageal adenocarcinomas
Journal of Cancer 2018, 9 (3), pp. 460-468.
IF 3.249, cited 2 times.
21. Jomrich G, Hollenstein M, John M, Baierl A, Paireder M, Kristo I, Ilhan-Mutlu A, Asari R, Preusser M, [Schoppmann SF](#).
The modified glasgow prognostic score is an independent prognostic indicator in neoadjuvantly treated adenocarcinoma of the esophagogastric junction
Oncotarget 2018, 9 (6), pp. 6968-6976.
IF 5.168, cited 4 times.
22. Paireder M, Jomrich G, Asari R, Kristo I, Gleiss A, Preusser M, [Schoppmann SF](#).
External validation of the NUn score for predicting anastomotic leakage after oesophageal resection
Scientific Reports 2017, Aug 29;7(1):9725
IF 4.122, cited 2 time.
23. Kollmann D, Schweiger T, Schwarz S, Ignatova D, Chang Y-T, Lewik G, [Schoppmann SF](#), Hoetzenecker W, Klepetko W, Guenova E, Hoetzenecker K.
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
OncoImmunology 2017, 6 (9), e1331194
IF 5.503, cited 8 times.
24. Kollmann D, Ignatova D, Jedamzik J, Chang Y-T, Jomrich G, Paireder M, Kristo I, Kazakov D, Michal M, Cozzio A, Hoetzenecker W, Schatton T, Asari R, Preusser M, Guenova E, [Schoppmann SF](#).
Expression of Programmed Cell Death Protein 1 by Tumor-Infiltrating Lymphocytes and Tumor Cells is Associated with Advanced Tumor Stage in Patients with Esophageal Adenocarcinoma
Annals of Surgical Oncology 2017, 24 (9), pp. 2698-2706.
IF 3.857, cited 7 times.
25. Ringhofer C, Lenglinger J, Riegler M, Kristo I, Kainz A, [Schoppmann SF](#).
Waist to hip ratio is a better predictor of esophageal acid exposure than body mass index
Neurogastroenterology and Motility 2017, 29 (7), art. no. e13033,
IF 3.842, cited 5 times.
26. Prusa AM, Kristo I, Rieder E, Ringhofer C, Asari R, Miholic J, [Schoppmann SF](#).
Tension-Free Inlay Repair of Large Hiatal Hernias Using Dual-Sided Composite PTFE/ePTFE Meshes in Laparoscopic Surgery for Gastroesophageal Reflux Disease
Journal of Laparoendoscopic and Advanced Surgical Techniques 2017, 27 (7), pp. 710-714.
IF 1.257, cited 3 time.

27. Rieder E, Asari R, Paireder M, Lenglinger J, [Schoppmann SF](#).
Endoscopic stent suture fixation for prevention of esophageal stent migration during prolonged dilatation for achalasia treatment
Diseases of the Esophagus 2017, 30 (4), pp. 1-6.
IF 2.702, cited 3 times.
28. Paireder M, Asari R, Kristo I, Rieder E, Tamandl D, Ba-Ssalamah A, [Schoppmann SF](#).
Impact of sarcopenia on outcome in patients with esophageal resection following neoadjuvant chemotherapy for esophageal cancer
European Journal of Surgical Oncology 2017, 43 (2), pp. 478-484.
IF 3.688 cited 28 times.
29. Jomrich G, Paireder M, Gleiss A, Kristo I, Harpain L, [Schoppmann SF](#).
Comparison of Inflammation-Based Prognostic Scores in a Cohort of Patients with Resectable Esophageal Cancer
Gastroenterology Research and Practice 2017, e1678584, .
IF 1.859, cited 7 times.
30. Dolak W, Beer A, Kristo I, Tribl B, Asari R, Schöniger-Hekele M, Wrba F, [Schoppmann SF](#), Trauner M, Püspök A.
A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors
Gastrointestinal Endoscopy 2016, 84 (6), pp. 924-929.
IF 7.204, cited 5 times.
31. Schiefer A-I, [Schoppmann SF](#), Birner P.
Lymphovascular invasion of tumor cells in lymph node metastases has a negative impact on survival in esophageal cancer
Surgery (United States) 2016, 160 (2), pp. 331-340.
IF 3.574, cited 11 times.
32. Tamandl D, Paireder M, Asari R, Baltzer PA, [Schoppmann SF](#), Ba-Ssalamah A.
Markers of sarcopenia quantified by computed tomography predict adverse long-term outcome in patients with resected oesophageal or gastro-oesophageal junction cancer
European Radiology 2016, 26 (5), pp. 1359-1367.
IF 4.027, cited 76 times.
33. Tamandl D, Ta J, Schmid R, Preusser M, Paireder M, [Schoppmann SF](#), Haug A, Ba-Ssalamah A.
Prognostic value of volumetric PET parameters in unresectable and metastatic esophageal cancer
European Journal of Radiology 2016, 85 (3), pp. 540-545.
IF 2.843, cited 14 times.
34. Drahos J, Schwameis K, Orzolek LD, Hao H, Birner P, Taylor PR, Pfeiffer RM, [Schoppmann SF*](#), Cook MB*.
MicroRNA profiles of Barrett's esophagus and esophageal adenocarcinoma: Differences in glandular non-native epithelium
Cancer Epidemiology Biomarkers and Prevention 2016, 25 (3), pp. 429-437. Authors contributed equally last
IF 4.554, cited 16 times.
35. Tamandl D, Gore RM, Fueger B, Kinsperger P, Hejna M, Paireder M, Haug A, [Schoppmann SF](#), Ba-Ssalamah A.
Change in volume parameters induced by neoadjuvant chemotherapy provide accurate prediction of overall survival after resection in patients with oesophageal cancer
European Radiology 2016, 26 (2), pp. 311-321.
IF 4.027, cited 14 times.
36. Kristo I, [Schoppmann SF](#), Riegler M, Püspök A, Emmanuel K, Spaun G, Wrba F, Wenzl E, Schöfl R, Schreiber F, Häfner M, Madl C.
Austrian expert panel recommendation for radiofrequency ablation of Barrett's esophagus
European Surgery - Acta Chirurgica Austriaca 2015, 47 (6), pp. 319-323.
IF 0.349, cited 4 times.
37. Schwarz C, Soliman T, Györi G, Silberhumer G, [Schoppmann SF](#), Mühlbacher F, Berlakovich GA.
Abdominal drainage after liver transplantation from deceased donors
Langenbeck's Archives of Surgery 2015, 400 (7), pp. 813-819.
IF 2.296, cited 2 time.
38. Kristo I, Riegler FM, Asari R, Cosentini E, [Schoppmann SF](#).
Selected commentary to "Treatment of Barrett's esophagus with a novel focal cryoablation device: a safety and feasibility study"
European Surgery - Acta Chirurgica Austriaca 2015, 47 (5), pp. 274-278.
IF 0.349, cited 1 time.

39. Zacherl J, Asari R, Fleischmann E, Karbon B, Rasoul-Rockenschaub S, Prager G, Riegler FM, [Schoppmann SF](#).
Fast-track Ivor Lewis esophageal resection
European Surgery - Acta Chirurgica Austriaca 2015, 47 (2), pp. 59-64.
IF 0.349, cited 4 times.
40. Ilhan-Mutlu A, Starlinger P, Perkmann T, [Schoppmann SF](#), Preusser M, Birner P.
Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer
Biomarkers in Medicine 2015, 9 (4), pp. 327-335.
IF 2.346, cited 14 times.
41. Dolak W, Mesteri I, Asari R, Preusser M, Tribl B, Wrba F, [Schoppmann SF](#), Hejna M, Trauner M, Hafner M, Püspök A
A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection
Endoscopy International Open 2015 ,3 (1), pp. E19-E28
IF no, cited 4 times.
42. Zacherl J, Roy-Shapira A, Bonavina L, Bapaye A, Kiesslich R, [Schoppmann SF](#), Kessler WR, Selzer DJ, Broderick RC, Lehman GA, Horgan S.
Endoscopic anterior fundoplication with the Medigus Ultrasonic Surgical Endostapler (MUSE™) for gastroesophageal reflux disease: 6-month results from a multi-center prospective trial
Surgical Endoscopy 2015, 29 (1), pp. 220-229.
IF 3.117, cited 53 times.
43. Ilhan-Mutlu A, Tezcan G, [Schoppmann SF](#), Preusser M, Spyridoula K, Karanikas G, Birner P.
MicroRNA-21 expression is elevated in esophageal adenocarcinoma after neoadjuvant chemotherapy
Cancer Investigation 2015, 33 (6), pp. 246-250.
IF 2.053, cited 5 times.
44. Birner P, Pusch S, Christov C, Mihaylova S, Toumangelova-Uzeir K, Natchev S, [Schoppmann SF](#), Tchorbantov A, Streubel B, Tuettenberg J, Guentchev M.
Mutant IDH1 inhibits PI3K/Akt signaling in human glioma
Cancer 2014, 120 (16), pp. 2440-2447.
IF 6.537, cited 34 times.
45. Aumayr K, Soleiman A, Sahara K, Schindl M, Werba G, [Schoppmann SF](#), Birner P.
HER2 gene amplification and protein expression in pancreatic ductal adenocarcinomas
Applied Immunohistochemistry and Molecular Morphology 2014, 22 (2), pp. 146-152.
IF 2.042, cited 19 times.
46. Mesteri I, [Schoppmann SF](#), Preusser M, Birner P.
Overexpression of CMET is associated with signal transducer and activator of transcription 3 activation and diminished prognosis in esophageal adenocarcinoma but not in squamous cell carcinoma
European Journal of Cancer 2014, 50 (7), pp. 1354-1360.
IF 7.191, cited 24 times.
47. Schwameis K, [Schoppmann SF](#), Stift J, Schwameis M, Stift A.
Small bowel adenocarcinoma - terra incognita: A demand for cross-national pooling of data
Oncology Letters 2014, 7 (5), pp. 1613-1617.
IF 1.664, cited 9 times.
48. Jomrich G, Jesch B, Birner P, Schwameis K, Paireder M, Asari R, [Schoppmann SF](#).
Stromal expression of carbonic anhydrase IX in esophageal cancer
Clinical and Translational Oncology 2014, 16 (11), pp. 966-972.
IF2.392, cited 17 times.
49. [Schoppmann SF](#), Ricken G, Ilhan-Mutlu A, Nirtl N, Streubel B, Preusser M, Birner P.
Downregulation of CIC does not associate with overexpression of ETV1 or MAP kinase pathway activation in gastrointestinal stromal tumors
Cancer Investigation 2014, 32 (7), pp. 363-367.
IF 2.053, cited 2 times.

50. Schwameis K, Schwameis M, Zörner B, Lenglinger J, Asari R, Riegler FM, [Schoppmann SF](#).
Modern GERD treatment: Feasibility of minimally invasive esophageal sphincter augmentation
Anticancer Research 2014, 34 (5), pp. 2341-2348.
IF 1.865, cited 26 times.
51. Mesteri I, Bayer G, Meyer J, Capper D, [Schoppmann SF](#), Von Deimling A, Birner P.
Improved molecular classification of serrated lesions of the colon by immunohistochemical detection of BRAF V600E
Modern Pathology 2014, 27 (1), pp. 135-144.
IF 6.655, cited 44 times.
52. Koperek O, Aumayr K, Schindl M, Wrba F, Soleiman A, [Schoppmann SF](#), Sahora K, Birner P.
Phosphorylation of STAT3 correlates with HER2 status, but not with survival in pancreatic ductal adenocarcinoma
APMIS 2014, 122 (6), pp. 476-481.
IF 2.026, cited 4 times.
53. Birner P, Berghoff AS, Dinhof C, Pirker C, Capper D, [Schoppmann SF](#), Petzelbauer P, von Deimling A, Berger W, Preusser M.
MAP kinase activity supported by BRAF V600E mutation rather than gene amplification is associated with ETV1 expression in melanoma brain metastases
Archives of Dermatological Research 2014, 306 (10), pp. 873-884.
IF 2.148, cited 3 times.
54. Sahora K, Schindl M, Kuehrer I, Eisenhut A, Werba G, Brostjan C, Telek B, Ba'Ssalamah A, Stift J, [Schoppmann SF](#), Gnant M.
A phase II trial of two durations of bevacizumab added to neoadjuvant gemcitabine for borderline and locally advanced pancreatic cancer
Anticancer Research 2014, 34 (5), pp. 2377-2384.
IF 1.865, cited 21 times.
55. Kandioler D, [Schoppmann SF](#), Zwrtek R, Kappel S, Wolf B, Mittlböck M, Kühner I, Hejna M, Pluschnig U, Ba-Ssalamah A, Wrba F, Zacherl J.
The biomarker TP53 divides patients with neoadjuvantly treated esophageal cancer into 2 subgroups with markedly different outcomes. A p53 Research Group study
Journal of Thoracic and Cardiovascular Surgery 2014, 148 (5), pp. 2280-2286.
IF 4.880, cited 35 times.
56. [Schoppmann SF](#), Vinatzer U, Popitsch N, Mittlböck M, Liebmann-Reindl S, Jomrich G, Streubel B, Birner P.
Novel clinically relevant genes in gastrointestinal stromal tumors identified by exome sequencing
Clinical Cancer Research 2013, 19 (19), pp. 5329-5339.
IF 10.199, cited 44 times.
57. Preusser M, Berghoff AS, Capper D, Von Deimling A, Maroske F, Brodowicz T, Hejna M, Birner P, [Schoppmann SF](#).
No evidence for BRAF-V600E mutations in gastroesophageal tumors: Results from a high-throughput analysis of 534 cases using a mutation-specific antibody
Applied Immunohistochemistry and Molecular Morphology 2013, 21 (5), pp. 426-430.
IF 2.042, cited 8 times.
58. Schwameis K, Fochtmann A, Schwameis M, Asari R, Schur S, Köstler W, Birner P, Ba-Ssalamah A, Zacherl J, Wrba F, Brodowicz T, [Schoppmann SF](#).
Surgical treatment of GIST - An institutional experience of a high-volume center
International Journal of Surgery 2013, 11 (9), pp. 801-806.
IF 2.693, cited 21 times.
59. Ilhan-Mutlu A, Preusser M, [Schoppmann SF](#), Asari R, Ba-Ssalamah A, Schwameis K, Pluschnig U, Birner P, Puspok A, Zacherl J, Hejna M.
Comparison between DCF (docetaxel, cisplatin and 5-fluorouracil) and modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for adenocarcinoma of the upper gastrointestinal tract
Anticancer Research 2013, 33 (8), pp. 3455-3460.
IF 1.865, cited 4 times.
60. [Schoppmann SF](#), Beer A, Nirtl N, Ba-Ssalamah A, Brodowicz T, Streubel B, Birner P.
Downregulation of phosphatidylethanolamine binding protein 1 associates with clinical risk factors in gastrointestinal stromal tumors, but not with activation of the RAF-1-MEK-ETV1 pathway
Cancer Letters 2013, 335 (1), pp. 26-30.
IF 6.491, cited 7 times.

61. [Schoppmann SF](#), Alidzanovic L, Schultheis A, Perkmann T, Brostjan C, Birner P.
Thrombocytes Correlate with Lymphangiogenesis in Human Esophageal Cancer and Mediate Growth of Lymphatic Endothelial Cells In Vitro
PLoS ONE 2013, 8 (6), art. no. e66941,
IF 2.766, cited 9 times.
62. Preusser M, Berghoff AS, Ilhan-Mutlu A, Magerle M, Dinhof C, Widhalm G, Dieckmann K, Marosi C, Wöhrer A, Hackl M, Zöchbauer-Müller S, von Deimling A, [Schoppmann SF](#), Zielinski CC, Streubel B, Birner P.
ALK gene translocations and amplifications in brain metastases of non-small cell lung cancer
Lung Cancer 2013, 80 (3), pp. 278-283.
IF 4.486, cited 44 times.
63. [Schoppmann SF](#), Streubel B, Birner P.
Amplification but not translocation of anaplastic lymphoma kinase is a frequent event in oesophageal cancer
European Journal of Cancer 2013, 49 (8), pp. 1876-1881.
IF 7.191, cited 15 times.
64. Schwameis K, Ba-Ssalamah A, Wrba F, Birner P, Prager G, Hejna M, Schmid R, Asari R, Zacherl J, [Schoppmann SF](#).
The implementation of minimally-invasive esophagectomy does not impact short-term outcome in a high-volume center
Anticancer Research 2013, 33 (5), pp. 2085-2091.
IF 1.865, cited 12 times
65. [Schoppmann SF](#), Jesch B, Zacherl J, Riegler MF, Friedrich J, Birner P.
Lymphangiogenesis and lymphovascular invasion diminishes prognosis in esophageal cancer
Surgery (United States) 2013, 153 (4), pp. 526-534.
IF 3.574, cited 51 times.
66. [Schoppmann SF](#), Jesch B, Riegler MF, Maroske F, Schwameis K, Jomrich G, Birner P.
Podoplanin expressing cancer associated fibroblasts are associated with unfavourable prognosis in adenocarcinoma of the esophagus
Clinical and Experimental Metastasis 2013, 30 (4), pp. 441-446.
IF 3.455, cited 65 times.
67. Preusser M, Capper D, Berghoff AS, Horvat R, Wrba F, Schindl M, [Schoppmann SF](#), Von Deimling A, Birner P.
Expression of BRAF V600E mutant protein in epithelial ovarian tumors
Applied Immunohistochemistry and Molecular Morphology 2013, 21 (2), pp. 159-164.
IF 2.042, cited 32 times.
68. Pluschnig U, [Schoppmann SF](#), Preusser M, Datler P, Asari R, Ba-Ssalamah A, Schwameis K, Birner P, Zacherl J, Hejna M.
Modified EOX (epirubicin, oxaliplatin and capecitabine) as palliative first-line chemotherapy for gastroesophageal adenocarcinoma
Anticancer Research 2013, 33 (3), pp. 1035-1040.
IF 1.865, cited 8 times.
69. Preusser M, Berghoff AS, Ilhan-Mutlu A, Dinhof C, Magerle M, Marosi C, Hejna M, Capper D, Von Deimling A, [Schoppmann SF](#), Birner P.
Brain metastases of gastro-oesophageal cancer: Evaluation of molecules with relevance for targeted therapies
Anticancer Research 2013, 33 (3), pp. 1065-1072.
IF 1.865, cited 16 times.
70. Bareck E, Ba-Ssalamah A, Brodowicz T, Eisterer W, Häfner M, Högenauer C, Kastner U, Kühr T, Längle F, Liegl-Atzwanger B, [Schoppmann SF](#), Widmann G, Wrba F, Zacherl J, Ploner F.
Gastrointestinal stromal tumors: Diagnosis, therapy and follow-up care in Austria
Wiener Medizinische Wochenschrift 2013, 163 (5-6), pp. 137-152.
IF 0,836, cited 14 times.
71. [Schoppmann SF](#), Langer FB, Prager G, Zacherl J.
Outcome and complications of long-term self-expanding esophageal stenting
Diseases of the Esophagus 2013, 26 (2), pp. 154-158.
IF 2.702, cited 29 times.
72. Panhofer P, Springer C, Izay B, Grasl M, Burian M, [Schoppmann SF](#), Rath T, Jakesz R, Zacherl J.
Influence of resection extent on morbidity in surgery for squamous cell cancer at the pharyngoesophageal junction
Langenbeck's Archives of Surgery 2013, 398 (2), pp. 221-230.
IF 2.296, cited 8 times.

73. Schindler A, Mozzanica F, Alfonsi E, Ginocchio D, Rieder E, Lenglinger J, [Schoppmann SF](#), Scharitzer M, Pokieser P, Kuribayashi S, Kawamura O, Kusano M, Zelenik K.
Upper esophageal sphincter dysfunction: Diverticula-globus pharyngeus
Annals of the New York Academy of Sciences 2013, 1300 (1), pp. 250-260.
IF 4.277, cited 10 times.
74. Mesteri I, Beller L, Fischer-See S, [Schoppmann SF](#), Lenglinger J, Wrba F, Riegler M, Zacherl J.
Radiofrequency ablation of Barrett's esophagus and early cancer within the background of the pathophysiology of the disease
European Surgery - Acta Chirurgica Austriaca 2012, 44 (6), pp. 366-382.
IF 0.349, cited 10 times.
75. Pilat N, [Schoppmann SF](#), Stift J, Mazal P, Wekerle T, Berlakovich GA.
No evidence for recipient-derived hepatocytes in serial biopsies of sex-mismatched liver transplants
Transplantation 2012, 94 (9), pp. 953-957.
IF 3.960, cited 7 times.
76. Mesteri I, Lenglinger J, Beller L, Fischer-See S, [Schoppmann SF](#), Wrba F, Riegler FM, Zacherl J.
Assessment of columnar-lined esophagus in controls and patients with gastroesophageal reflux disease with and without proton-pump inhibitor therapy
European Surgery - Acta Chirurgica Austriaca 2012, 44 (5), pp. 304-313.
IF 0.349, cited 9 times.
77. Birner P, Jesch B, Schultheis A, [Schoppmann SF](#).
RAF-kinase inhibitor protein (RKIP) downregulation in esophageal cancer and its metastases
Clinical and Experimental Metastasis 2012, 29 (6), pp. 551-559.
IF 3.455 ,cited 29 times.
78. [Schoppmann SF](#), Jesch B, Friedrich J, Jomrich G, Maroske F, Birner P.
Phosphorylation of signal transducer and activator of transcription 3 (STAT3) correlates with Her-2 status, carbonic anhydrase 9 expression and prognosis in esophageal cancer
Clinical and Experimental Metastasis 2012, 29 (6), pp. 615-624.
IF 3.455 cited 32 times.
79. [Schoppmann SF](#), Berghoff A, Dinhof C, Jakesz R, Gnant M, Dubsy P, Jesch B, Heinzl H, Birner P.
Podoplanin-expressing cancer-associated fibroblasts are associated with poor prognosis in invasive breast cancer
Breast Cancer Research and Treatment 2012, 134 (1), pp. 237-244.
IF 3.605, cited 68 times.
80. [Schoppmann SF](#), Berghoff AS, Jesch B, Zacherl J, Nirtl N, Jomrich G, Maroske F, Streubel B, Mesteri I, Birner P.
Expression of podoplanin is a rare event in sporadic gastrointestinal stromal tumors and does not influence prognosis
Future Oncology 2012, 8 (7), pp. 859-866.
IF 2.369, cited 10 times.
81. Maresch J, [Schoppmann SF](#), Thallinger CMR, Zielinski CC, Hejna M.
Her-2/neu gene amplification and over-expression in stomach and esophageal adenocarcinoma: From pathology to treatment
Critical Reviews in Oncology/Hematology 2012, 82 (3), pp. 310-322.
IF 4.495, cited 19 times.
82. Birner P, Schoppmann A, Schindl M, Dinhof C, Jesch B, Berghoff AS, [Schoppmann SF](#).
Human homologue for Caenorhabditis elegans CUL-4 protein overexpression is associated with malignant potential of epithelial ovarian tumours and poor outcome in carcinoma
Journal of Clinical Pathology 2012, 65 (6), pp. 507-511.
IF 2.894, cited 31 times.
83. Birner P, Beer A, Vinatzer U, Stary S, Hoftberger R, Nirtl N, Wrba F, Streubel B, [Schoppmann SF](#).
MAPKAP kinase 2 overexpression influences prognosis in gastrointestinal stromal tumors and associates with copy number variations on chromosome 1 and expression of p38 MAP kinase and ETV1
Clinical Cancer Research 2012, 18 (7), pp. 1879-1887.
IF 10.199, cited 30 times.

84. Schoppmann A, Tamandl D, Herberger B, Längle F, Birner P, Geleff S, Grünberger T, [Schoppmann SF](#). **Comparison of lymphangiogenesis between primary colorectal cancer and corresponding liver metastases** Anticancer Research 2012, 31 (12), pp. 4605-4611. IF 1.865, cited 15 times.
85. Pertl L, Zacherl J, Mancusi G, Gächter JN, Asari R, [Schoppmann SF](#), Bigenzahn W, Schneider-Stickler B. **High risk of unilateral recurrent laryngeal nerve paralysis after esophagectomy using cervical anastomosis** European Archives of Oto-Rhino-Laryngology 2011, 268 (11), pp. 1605-1610. IF 1.546, cited 24 times.
86. Birner P, Jesch B, Friedrich J, Riegler M, Zacherl J, Hejna M, Wrba F, Schultheis A, [Schoppmann SF](#). **Carbonic anhydrase IX overexpression is associated with diminished prognosis in esophageal cancer and correlates with Her-2 expression** Annals of Surgical Oncology 2011, 18 (12), pp. 3330-3337. IF 3.857, cited 32 times.
87. Ba-Ssalamah A, Matzek W, Baroud S, Bastati N, Zacherl J, [Schoppmann SF](#), Hejna M, Wrba F, Weber M, Herold CJ, Gore RM. **Accuracy of hydro-multidetector row CT in the local T staging of oesophageal cancer compared to postoperative histopathological results** European Radiology 2011, 21 (11), pp. 2326-2335. IF 4.027, cited 32 times.
88. [Schoppmann SF](#), Jesch B, Zacherl J, Wrba F, Hejna M, Maresch J, Langer FB, Riegler MF, Pluschnig U, Birner P. **HER-2 status in primary oesophageal cancer, lymph nodes and distant metastases** British Journal of Surgery 2011, 98 (10), pp. 1408-1413. IF 5.433, cited 30 times.
89. Bojic M, Pluschnig U, Zacherl J, Thallinger CMR, Ba-Ssalamah A, Maresch J, Datler P, [Schoppmann SF](#), Hejna M. **Docetaxel, cisplatin and 5-fluorouracil plus granulocyte colony-stimulating factor prophylaxis in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: Experience at the Medical University of Vienna** Anticancer Research 2011, 31 (6), pp. 2379-2382. IF 1.865, cited 5 times.
90. Starlinger P, Alidzanovic L, Schauer D, Brugger P, Sommerfeldt S, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C. **Platelet-stored angiogenesis factors: Clinical monitoring is prone to artifacts** Disease Markers 2011, 31 (2), pp. 55-65. IF 2.949, cited 31 times.
91. Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C. **Myelosuppression of thrombocytes and monocytes is associated with a lack of synergy between chemotherapy and Anti-VEGF treatment** Neoplasia 2011, 13 (5), pp. 419-427. IF 4.994, cited 15 times.
92. Starlinger P, Brugger P, Reiter C, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C. **Discrimination between circulating endothelial cells and Blood cell populations with overlapping phenotype reveals distinct regulation and predictive potential in Cancer therapy** Neoplasia 2011, 13 (10), pp. 980-990. IF 4.994, cited 15 times.
93. [Schoppmann SF](#), Jesch B, Friedrich J, Wrba F, Schultheis A, Pluschnig U, Maresch J, Zacherl J, Hejna M, Birner P. **Expression of her-2 in carcinomas of the esophagus** American Journal of Surgical Pathology 2010, 34 (12), pp. 1868-1873. IF 5.878, cited 59 times.
94. Starlinger P, Moll HP, Assinger A, Nemeth C, Hoetzenecker K, Gruenberger B, Gruenberger T, Kuehrer I, [Schoppmann SF](#), Gnant M, Brostjan C. **Thrombospondin-1: A unique marker to identify in vitro platelet activation when monitoring in vivo processes** Journal of Thrombosis and Haemostasis 2010, 8 (8), pp. 1809-1819. IF 4.899, cited 37 times.

95. Langer FB, Bohdjalian A, Shakeri-Leidenmühler S, [Schoppmann SF](#), Zacherl J, Prager G.
Conversion from sleeve gastrectomy to roux-en-y gastric bypass-indications and outcome
Obesity Surgery 2010, 20 (7), pp. 835-840.
IF 3.890, cited 132 times.
96. Langer FB, Shakeri-Leidenmühler S, Bohdjalian A, [Schoppmann SF](#), Zacherl J, Felberbauer FX, Vila G, Prager G.
Strategies for weight regain after sleeve gastrectomy
Surgical Laparoscopy, Endoscopy and Percutaneous Techniques 2010, 20 (3), pp. 159-161.
IF 0.986, cited 17 times.
97. Langer FB, [Schoppmann SF](#), Prager G, Riegler FM, Zacherl J.
Solving the Problem of Difficult Stent Removal Due to Tissue Ingrowth in Partially Uncovered Esophageal Self-Expanding Metal Stents
Annals of Thoracic Surgery 2010, 89 (5), pp. 1691-1692.
IF 3.780, cited 21 times.
98. Langer FB, [Schoppmann SF](#), Prager G, Tomaselli F, Pluschnig U, Hejna M, Schmid R, Zacherl J.
Temporary placement of self-expanding oesophageal stents as bridging for neo-adjuvant therapy
Annals of Surgical Oncology 2010, 17 (2), pp. 470-475.
IF 3.857, cited 59 times.
99. [Schoppmann SF](#), Prager G, Langer FB, Riegler FM, Kabon B, Fleischmann E, Zacherl J.
Open versus minimally invasive esophagectomy: A single-center case controlled study
Surgical Endoscopy 2010, 24 (12), pp. 3044-3053.
IF 3.117, cited 110 times.
100. Panhofer P, Izay B, Schwameis K, [Schoppmann SF](#), Prager G, Jakesz R, Riegler FM, Zacherl J.
Gastrointestinal reconstructions in 1200 patients with cancer at the pharyngoesophageal junction
European Surgery - Acta Chirurgica Austriaca 2010, 42 (1), pp. 38-48.
IF 0.349, cited 3 times.
101. [Schoppmann SF](#), Tamandl D, Roberts L, Jomrich G, Schoppmann A, Zwrtek R, Dubsky P, Gnant M, Jakesz R, Birner P.
HER2/neu expression correlates with vascular endothelial growth factor-C and lymphangiogenesis in lymph node-positive breast cancer
Annals of Oncology 2009, 21 (5), pp. 955-960.
IF 13.930 cited 59 times.
102. Silberhumer GR, Györi G, Burghuber C, Neumayer C, Riegler M, Jakesz R, Prager G, [Schoppmann SF](#), Zacherl J.
The value of protecting the longitudinal staple line with invaginating sutures during esophageal reconstruction by gastric tube pull-up
Digestive Surgery 2009, 26 (4), pp. 337-341.
IF 2.031, cited 20 times.
103. [Schoppmann SF](#), Prager G, Langer F, Riegler M, Fleischman E, Zacherl J.
Fifty-five minimally invasive esophagectomies: A single centre experience
Anticancer Research 2009, 29 (7), pp. 2719-2725.
IF 1.865, cited 32 times.
104. Silberhumer GR, Hufschmid M, Wrba F, Gyoeri G, [Schoppmann SF](#), Tribl B, Wenzl E, Prager G, Laengle F, Zacherl J.
Surgery for gastrointestinal stromal tumors of the stomach
Journal of Gastrointestinal Surgery 2009, 13 (7), pp. 1213-1219.
IF 2.813, cited 68 times.
105. Blaha P, Exner R, Dal Borgo A, Bigenzahn S, Panhofer P, Riedl O, [Schoppmann SF](#), Bachleitner-Hofmann T, Sporn E, Pluschnig U, Fitzal F, Steger G, Jakesz R, Dubsky P, Gnant M.
Is endocrine therapy really pleasant? considerations about the long-term use of antihormonal therapy and its benefit/side effect ratio
Breast Care 2009, 4 (3), pp. 155-161.
IF 2.028, cited 3 times.
106. Gnant M, Dubsky P, Fitzal F, Blaha P, [Schoppmann SF](#), Steger G, Marth C, Samonigg H, Hüttner K, Fohler H, Ruecklinger E, Jakesz R, Greil R.
Maintaining bone density in patients undergoing treatment for breast cancer: Is there an adjuvant benefit?
Clinical Breast Cancer 2009, 9 (SUPPL.1), pp. S18-S27.
IF 2.703, cited 14 times.

107. Kappel S, Bichler C, Wolf B, Gacic S, [Schoppmann SF](#), Devyatko Y, Prager G, Ba-SSalamah A, Wrba F, Pluschnig U, Kührer I, Mittlböck M, Hejna M, Zacherl J, Kandioler D, Zacherl J.
Turning the tables on surgical oncology: The • Pancho trial unplugged
European Surgery - Acta Chirurgica Austriaca 2008, 40 (6), pp. 277-283.
IF 0.349, cited 7 times.
108. Tamandl D, Herberger B, Gruenberger B, [Schoppmann SF](#), Puhalla H, Schindl M, Schima W, Jakesz R, Gruenberger T.
Adequate preoperative staging rarely leads to a change of intraoperative strategy in patients undergoing surgery for colorectal cancer liver metastases
Surgery 2008, 143 (5), pp. 648-657.
IF 3.574, cited 35 times.
109. Schindl M, Gnant M, [Schoppmann SF](#), Horvat R, Birner P.
Overexpression of the human homologue for Caenorhabditis elegans cul-4 gene is associated with poor outcome in node-negative breast cancer
Anticancer Research 2007, 27 (2), pp. 949-952.
IF 1.865, cited 55 times.
110. Tamandl D, Gruenberger B, Herberger B, [Schoppmann SF](#), Bodingbauer M, Schindl M, Puhalla H, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T.
Selective resection of colorectal liver metastases
European Journal of Surgical Oncology 2007, 33 (2), pp. 174-182.
IF 3.688, cited 47 times.
111. [Schoppmann SF](#), Fenzl A, Schindl M, Bachleitner-Hofmann T, Nagy K, Gnant M, Horvat R, Jakesz R, Birner P.
Hypoxia inducible factor-1 α correlates with VEGF-C expression and lymphangiogenesis in breast cancer
Breast Cancer Research and Treatment 2006, 99 (2), pp. 135-141.
IF 2.028, cited 131 times.
112. [Schoppmann SF](#), Fenzl A, Nagy K, Unger S, Bayer G, Geleff S, Gnant M, Horvat R, Jakesz R, Birner P.
VEGF-C expressing tumor-associated macrophages in lymph node positive breast cancer: impact on lymphangiogenesis and survival
Surgery 2006, 139 (6), pp. 839-846.
IF 3.574, cited 170 times.
113. Fenzl A, [Schoppmann SF](#), Geleff S, Birner P, Wrba F, Herberger B, Teleky B, Herbst F, Kührer I, Jakesz R, Längle F.
Vascular endothelial growth factor-C expression and lymphangiogenesis in colorectal cancer
European Surgery - Acta Chirurgica Austriaca 2006, 38 (2), pp. 149-154.
IF 0.349, cited 5 times.
114. Bachleitner-Hofmann T, Strohschneider M, Krieger P, Sachet M, Dubsky P, Hayden H, [Schoppmann SF](#), Pfragner R, Gnant M, Friedl J, Stift A.
Heat shock treatment of tumor lysate-pulsed dendritic cells enhances their capacity to elicit antitumor T cell responses against medullary thyroid carcinoma
Journal of Clinical Endocrinology and Metabolism 2006, 91 (11), pp. 4571-4577.
IF 5.789, cited 32 times.
115. [Schoppmann SF](#), Bayer G, Aumayr K, Taucher S, Geleff S, Rudas M, Kubista E, Hausmaninger H, Samonigg H, Gnant M, Jakesz R, Horvat R.
Prognostic value of lymphangiogenesis and lymphovascular invasion in invasive breast cancer
Annals of Surgery 2004, 240 (2), pp. 306-312.
IF 9.203, cited 326 times.
116. [Schoppmann SF](#), Soleiman A, Kalt R, Okubo Y, Benisch C, Nagavarapu U, Herron GS, Geleff S.
Telomerase-immortalized lymphatic and blood vessel endothelial cells are functionally stable and retain their lineage specificity
Microcirculation 2004, 11 (3), pp. 261-269.
IF 2.797, cited 29 times.
117. Valencak J, Heere-Ress E, Kopp T, [Schoppmann SF](#), Kittler H, Pehamberger H.
Selective immunohistochemical staining shows significant prognostic influence of lymphatic and blood vessels in patients with malignant melanoma
European Journal of Cancer 2004, 40 (3), pp. 358-364.
IF 7.191, cited 78 times.

118. [Schoppmann SF](#), Schindl M, Bayer G, Aumayr K, Dienes J, Horvat R, Rudas M, Gnant M, Jakesz R, Birner P.
Overexpression of Id-1 is associated with poor clinical outcome in node negative breast cancer
International Journal of Cancer 2004, 104 (6), pp. 677-682.
IF 7.360, cited 193 times.
119. Geleff S, [Schoppmann SF](#), Oberhuber G.
Increase in podoplanin-expressing intestinal lymphatic vessels in inflammatory bowel disease
Virchows Archiv 2003, 442 (3), pp. 231-237.
IF 2,848, cited 74 times.
120. Schindl M*, [Schoppmann SF*](#), Ströbel T, Heinzl H, Leisser C, Horvat R, Birner P.
Level of Id-1 protein expression correlates with poor differentiation, enhanced malignant potential, and more aggressive clinical behavior of epithelial ovarian tumors
Clinical Cancer Research 2003, 9 (2), pp. 779-785.
IF 10.199, cited 183 times.* contributed equally first author
121. [Schoppmann SF](#), Birner P, Stöckl J, Kalt R, Ullrich R, Caucig C, Nagy K, Alitalo K, Kerjaschki D.
Tumor-associated macrophages express lymphatic endothelial growth factors and are related to peritumoral lymphangiogenesis
American Journal of Pathology 2002, 161 (3), art. no. 64255, pp. 947-956.
IF 4.069, cited 842 times.
122. Schindl M, [Schoppmann SF](#), Samonigg H, Hausmaninger H, Kwasny W, Gnant M, Jakesz R, Kubista E, Birner P, Oberhuber
Overexpression of hypoxia-inducible factor 1 α is associated with an unfavorable prognosis in lymph node-positive breast cancer
Clinical Cancer Research 2002, 8 (6), pp. 1831-1837.
IF 10.199, cited 468 times.
123. [Schoppmann SF](#), Schindl M, Breiteneder-Geleff S, Soleiman A, Breiteneker G, Karner B, Birner P.
Inflammatory stromal reaction correlates with lymphatic microvessel density in early-stage cervical cancer
Anticancer Research 2001, 21 (5), pp. 3419-3423.
IF 1.865, cited 49 times.
124. [Schoppmann SF](#), Birner P, Studer P, Breiteneder-Geleff S.
Lymphatic microvessel density and lymphovascular invasion assessed by anti-podoplanin immunostaining in human breast cancer
Anticancer Research 2001, 21 (4 A), pp. 2351-2355.
IF 1.865, cited 187 times.
125. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, [Schoppmann SF](#), Stingl G, Kerjaschki D, Maurer D.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages
Journal of Experimental Medicine 2001, 194 (6), pp. 797-808.
IF 10.790, cited 543 times.
126. Schindl M, Oberhuber G, Obermair A, [Schoppmann SF](#), Karner B, Birner P.
Overexpression of Id-1 protein is a marker for unfavorable prognosis in early-stage cervical cancer
Cancer Research 2001, 61 (15), pp. 5703-5706.
IF 9.130, cited 218 times.

3.3.2 Publications in peer-reviewed journals (reviews, meeting abstracts, comments and guidelines) (IF taken from Journal Citation Reports, Thomson Reuters 2017)

1. [Schoppmann SF](#), Kristo I, Riegler M.
Does anti-reflux surgery disrupt the pathway of Barrett's esophagus progression to cancer?
Translational Gastroenterology and Hepatology 2018, 3 (December), art. no. 101,
cited 1 time.
2. Rieder E, Riegler M, Simić AP, Skrobić OM, Bonavina L, Gursk, R, Paireder M, Castell DO, [Schoppmann SF](#).
Alternative therapies for GERD: A way to personalized antireflux surgery
Annals of the New York Academy of Sciences 2018, Dec;1434(1):360-369.
IF 4.277, cited 3 times.

3. Jomrich G, Hollenstein M, John M, Ristl R, Paireder M, Kristo I, Asari R, Gnant M, [Schoppmann SF](#).
Elevated Mean Corpuscular Volume Predicts Poor Outcome in Patients With Adenocarcinomas of the Esophagogastric Junction
Journal of the American College of Surgeons 2018, 227 (4), pp. E215-E215
IF 4.767
4. Jomrich G, Paireder M, Kristo I, Baierl A, Ilhan-Mutlu A, Preusser M, Asari R, Gnant M, [Schoppmann SF](#).
No Difference of the Systemic Immune-Inflammation Index as Prognostic Factor for Patients with Adenocarcinoma of the Gastroesophageal Junction With or Without Neoadjuvant Treatment
Journal of the American College of Surgeons 2018, 227 (4), pp. S245-S246
IF 4.767
5. Labenz J, Thattamparambil P, Gutt C, Nieponice A, Menke V, Madisch A, Weise R, [Schoppmann SF](#), Pedersen JB, Eypasch EP, Benedix F, Bouvy ND, Hesselbarth N.
Interim results of a prospective multi-center registry of lower esophageal sphincter stimulation of GERD: the lessgerd registry
Gastroenterology 2018, Meeting Abstract 443, 154 (4) pp: S101-S101
IF 20.773, cited 2 times.
6. Chang Y, Ignatova D, Kollmann D, Schweiger T, Schwarz S, Lewik G, [Schoppmann SF](#), Hoetzenecker W, French LE, Klepetko W, Hoetzenecker K, Guenova E.
PD1-positive tumor-infiltrating lymphocytes are associated with poor clinical outcome after pulmonary metastasectomy for colorectal cancer
Journal of investigative Dermatology 2018, Meeting Abstract 494, 138 (5) pp: S84-S84
IF 6.448
7. Ignatova D, Kollmann D, Jedamzik J, Chang Y, Jomrich G, Baierl A, Kazakov D, Michal M, Hoetzenecker W, Schatton T, French LE, Asari R, Preusser M, Gnant M, [Schoppmann SF*](#), Guenova E.*,
PD-L1 expression is an independent predictor of favorable outcome in patients with localized esophageal adenocarcinoma
Journal of investigative Dermatology 2018, Meeting Abstract 595, 138 (5), pp. S101-S101, *equally last author
IF 6.448
8. Gruber ES, Birner P, Merkel O, Bergmann MM, [Schoppmann SF](#), Park J, Moriggl R, Tse W, Kenner L.
The coactivator oncogene AF1Q associates with STAT3 activation downstream of MET action in gastro-esophageal cancer patients
Cancer Research 2017, Meeting Abstract 4463, 77 (Suppl. 13)
IF 9.130
9. Riegler M, Kristo I, Nikolic M, Rieder E, [Schoppmann SF](#).
Update on the management of Barrett's esophagus in Austria
European Surgery - Acta Chirurgica Austriaca 2017, 49 (6), pp. 282-287.
IF 0.349, cited 5 times.
10. Riegler M, Kristo I, Asari R, Rieder E, [Schoppmann SF](#).
Dietary sugar and Barrett's esophagus
European Surgery - Acta Chirurgica Austriaca 2017, 49 (6), pp. 279-281.
IF 0.349, cited 3 times.
11. Rieder E, Asari R, Paireder M, Preusser M, Birner P, [Schoppmann SF](#).
Immediate Surgery and Not Preoperative Chemotherapy Improves Recurrence-Free Interval in Patients With cT2 Esophageal Cancer
Gastroenterology 2016, Meeting Abstract Tu1275, 150 (4) pp. S1249-S1249
IF 20.773
12. Jomrich G, [Schoppmann SF](#).
Targeted therapy in gastric cancer
European Surgery - Acta Chirurgica Austriaca 2016, 48 (5), pp. 278-284.
IF 0.349, cited 15 times.
13. Jomrich G, [Schoppmann SF](#).
Targeting HER 2 and angiogenesis in gastric cancer
Expert Review of Anticancer Therapy 2016, 16 (1), pp. 111-122.
IF 2.347, cited 10 times.

14. Kristo I, Riegler M, [Schoppmann SF](#).
Should antireflux surgery be considered after successful endoscopic treatment of Barrett's esophagus with dysplasia and early cancer?
Endoscopy 2016, 48 (1), p. 92.
IF 6.629, cited 2 time.
15. Lenglinger J, Riegler M, [Schoppmann SF](#).
Barrett's esophagus and antireflux surgery: Wraps, rings, and HALOs
Annals of Surgery 2015, 261 (2), p. e49.
IF 9.203
16. Ilhan-Mutlu A, Starlinger P, Perkmann T, [Schoppmann SF](#), Preusser M, Birner P.
Erratum : Plasma fibrinogen and blood platelet counts are associated with response to neoadjuvant therapy in esophageal cancer
Biomarkers in Medicine 2015, 9 (6), p. 617.
IF 2.346
17. Rieder E, Lenglinger J, Spaun GO, Mari S, Asari R, Swanstrom LL, [Schoppmann SF](#).
Implementation of PerOral Endoscopic Myotomy (POEM) and Prolonged Dilatation As Treatment for Achalasia: Is It Worth the Cost?
Gastrointestinal Endoscopy 2015, Meeting Abstract: Tu1510, 81 (5), pp. AB490-AB491
IF 7.204
18. Lenglinger J, Kristo I, Scharitzer M, Rieder E, [Schoppmann SF](#).
Lower Esophageal Sphincter Dilation Using a Balloon Incorporating Impedance Planimetry Imaging (Esoflip (R)): Feasibility and Initial Experience in the Treatment of Patients With Achalasia
Gastroenterology 2015, Meeting Abstract: Tu1154, 148 (4), pp: S805-S805, Supp. 1
IF 20.773, cited 1 time.
19. Lenglinger J, Rieder E, Scharitzer M, Kristo I, [Schoppmann SF](#).
Impedance Planimetry (EndoFLIP (R)) Measurements at the Esophago-Gastric Junction Distinguish Neuromuscular Disorders From Fibrotic Lesions in Dysphagia Patients
Gastroenterology 2015, Meeting Abstract: Tu1153, 148 (4), pp: S805-S805, Supp. 1
IF 20.773
20. Kristo I, Riegler M, [Schoppmann SF](#).
Laryngopharyngeal reflux COPD to uncover reflux and columnar lined esophagus
International Journal of COPD 2015, 10 (1), pp. 2095-2096.
IF 2.917, cited 1 time.
21. Kristo I, [Schoppmann SF](#).
Diagnosis and treatment of benign inflammatory esophageal diseases
European Surgery - Acta Chirurgica Austriaca 2015, 47 (4), pp. 188-198.
IF 0.349, cited 7 times.
22. Kristo I, Asari R, Rieder E, Riegler M, [Schoppmann SF](#).
Treatment of Barrett's esophagus: Update on new endoscopic surgical modalities
Minerva Chirurgica 2015, 70 (2), pp. 107-118.
IF 0.554, cited 8 times.
23. Riegler M, Schwameis K, Asari R, [Schoppmann SF](#).
Otolaryngeal GERD symptoms and barrett esophagus: Implications for cancer prevention
Journal of Clinical Gastroenterology 2014, 48 (2), p. 191.
IF 2.968, cited 1 time.
24. [Schoppmann SF](#).
Surgical controversies in esophageal cancer
Memo - Magazine of European Medical Oncology 2014, 7 (1), pp. 30-33.
cited 11 times.

25. Riegler M, [Schoppmann SF](#).
Selected commentary to "Radiofrequency ablation vs endoscopic surveillance for patients with Barrett esophagus and low-grade dysplasia. A randomized clinical trial"
European Surgery - Acta Chirurgica Austriaca 2014, 46 (3), pp. 133-136.
IF 0.349, cited 1 times.
26. Riegler M, Asari R, [Schoppmann SF](#).
Face Barrett's: Esophageal Adenocarcinoma Affects the Young
Journal of Gastrointestinal Surgery 2014, 18 (4), pp. 882-883.
IF 2.813, cited 1 time.
27. Riegler M, Asari R, Cosentini EP, Wrba F, [Schoppmann SF](#).
Critical assessment of a new endoscopic anatomic concept for the so-called cardia in the sense of the notions of parmenides and martin heidegger Zeitschrift fur Gastroenterologie 2014, 52 (4), pp. 367-373.
IF 1.612, cited 6 times.
28. Schwarz C, Soliman T, Gyori G, Silberhumer G, [Schoppmann SF](#), Muhlbacher F, Berlakovich GA.
To drain or not to drain after liver transplantation
Transplant International 2014, Meeting Abstract: EP-23, 27 (SI) pp. 19-20, Supp. 2
IF 3.196
29. Rieder E, Asari R, Lenglinger J, [Schoppmann SF](#).
Endolumenal Stent Suture-Fixation Compared to Endoscopic Clips for Prevention of Esophageal Stent Migration During Prolonged Dilatation in Recurrent Achalasia
Gastroenterology 2014, Meeting Abstract: Su1806, 146 (5), pp. S1041-S1041, Supp. 1
IF 20.773, cited 2 times.
30. Pilat N, [Schoppmann SF](#), Mazal P, Stift J, Wekerle T, Berlakovich GA.
Serial Biopsies of Sex-Mismatched Liver Transplants Show No Evidence for Recipient-Derived Hepatocytes
Transplantation 2014, Meeting Abstract: 1992, 94 (10), pp. 225-225, Supp. S
IF 3.960
31. Roy-Shapira A, Bapaye A, Kiesslich R, Horgan S, [Schoppmann SF](#), Zacherl J, Bonavina L, Lehman GA.
Effective Endoscopic Treatment of Gastroesophageal Reflux Disease Using a New Endoscopic Stapling System Results of a Prospective Controlled Multicenter Trial
Gastroenterology 2014, 142 (5), pp. S1076-S1076, Supp.1
IF 20.773, cited 1 time
32. Asari R, Riegler M, [Schoppmann SF](#).
Dilated distal esophagus: Optimal position for magnetic sphincter augmentation
Journal of the American College of Surgeons 2013, 217 (6), pp. 1155-1156.
IF 4.767, cited 1 time.
33. Lenglinger J, See SF, Beller L, Cosentini EP, Asari R, Wrba F, Riegler M, [Schoppmann SF](#).
Review on novel concepts of columnar lined esophagus
Wiener Klinische Wochenschrift 2013, 125 (19-20), pp. 577-590.
IF 1.003, cited 6 times.
34. Asari R, Riegler M, [Schoppmann SF](#).
Extending Barrett's esophagus cancer risk profile towards genetic abnormalities
Molecular Cytogenetics 2013, 6 (1), art. no. 10, .
IF 1.167, cited 1 time.
35. [Schoppmann SF](#), Asari R, Riegler M.
Barrett's esophagus as a marker for increased risk for esophageal cancer and cardiorespiratory disease
Endoscopy 2013, 45 (2), p. 152.
IF 6.629, cited 3 times.

36. Lenglinger J, See SF, Beller L, Cosentini E, Asari R, Wrba F, Riegler M, [Schoppmann SF](#).
The cardia: esophageal or gastric? Critical reviewing the anatomy and histopathology of the esophagogastric junction.
Acta chirurgica Iugoslavica 2012, 59 (3), pp. 15-26.
cited 4 times.
37. Lenglinger J, Riegler M, Cosentini E, Asari R, Mesteri I, Wrba F, [Schoppmann SF](#).
Review on the annual cancer risk of Barrett's esophagus in persons with symptoms of gastroesophageal reflux disease
Anticancer Research 2012, 32 (12), pp. 5465-5474.
IF 1.865, cited 15 times.
38. [Schoppmann SF](#), Riegler MF.
Radial esophageal acid exposure and the dilated distal esophagus
Journal of Gastroenterology 2012, 47 (11), pp. 1275-1276.
IF 5.561
39. Lenglinger J, Riegler M, [Schoppmann SF](#).
Gastroesophageal reflux disease and metabolic syndrome
Internal Medicine 2012, 51 (20), p. 2993.
IF 0.817, cited 1 time.
40. Lenglinger J, Riegler M, [Schoppmann SF](#).
Letter: Cancer risk among persons with columnar-lined oesophagus
Alimentary Pharmacology and Therapeutics 2012, 36 (6), p. 599.
IF 7.357, cited 1 time.
41. [Schoppmann SF](#), Azari R, Riegler FM.
Selected commentary to "incidence of adenocarcinoma among patients with Barrett's esophagus"
European Surgery - Acta Chirurgica Austriaca 2012, 44 (4), pp. 291-295.
IF 0.349
42. Pilat N, Mazal P, Stift J, [Schoppmann SF](#), Wekerle T, Berlakovich GA.
No Evidence for Recipient-Derived Hepatocytes in Serial Biopsies of Sex-Mismatched Liver Transplants.
American Journal of Transplantation 2012, Meeting Abstract: 922 ,12(SI), pp. 297-297 Supp. 3
IF 6.493
43. Schwarz C, [Schoppmann SF](#), Gyori G, Silberhumer G, Soliman T, Steininger R, Muhlbacher F, Berlakovich G.
To Drain or Not To Drain after Liver Transplantation
Liver Transplantation 2012, 18, pp. S271-S271, Supp. 1
IF 3.756
44. Birner P, [Schoppmann SF](#).
Her-2 in gastroesophageal cancer: Pathobiology, diagnostic and therapeutic implications
European Surgery - Acta Chirurgica Austriaca 2011, 43 (3), pp. 162-167.
IF 0.349, cited 3 times.
45. Birner P, Jesch B, [Schoppmann SF](#).
Her-2 in carcinomas of the esophagus and its metastases
Virchows Archiv 2011, 459, pp. S15-S15, Supp. 1
IF 2.936
46. Brostjan C, Starlinger P, Brugger P, Schauer D, Sommerfeldt S, Tamandl D, Kuehrer I, [Schoppmann SF](#), Gnant M.
The role of myelosuppression in synergy between chemotherapy and anti-VEGF treatment
Journal of Clinical Oncology 2011, Meeting Abstract: e13527, 29 (15), Supp. S
IF 26.360
47. Pluschnig U, Zacherl J, [Schoppmann SF](#), Raderer M, Prager G, Bartsch R, Ba-Ssalamah A, Lamm W, Zielinski C, Hejna M.
Locally advanced gastric cancer treated with neoadjuvant chemotherapy: Epirubicin, oxaliplatin, and capecitabine (EOX)
Journal of Clinical Oncology 2011, Meeting Abstract: 136, 29 (4), Supp. S
IF 26.360

48. Kriehuber E, Breiteneder-Geleff S, Groeger M, Soleiman A, Schoppmann SF, Stingl G, Kerjaschki D, Maurer D.
Isolation and characterization of dermal lymphatic and blood endothelial cells reveal stable and functionally specialized cell lineages
Journal of Investigative Dermatology 2011, Meeting Abstract: 013117 (6), pp. 1680-1680
IF 6.448
49. Pluschnig U, Zacherl J, Schoppmann SF, Raderer M, Prager G, Bartsch R, Ba-Ssalamah A, Lamm W, Zielinski C, Hejna M.
Neoadjuvant chemotherapy in locally advanced gastric cancer with epirubicin, oxaliplatin, and capecitabine (EOX): A retrospective analysis
Journal of Clinical Oncology 2010, Meeting Abstract: e14682, 28 (15), Supp. S
IF 26.360
50. Starlinger P, Nemeth C, Schoppmann SF, Kuehrer I, Gnant M, Gruenberger B, Gruenberger T, Brostjan C.
Monitoring of Angiogenic Factors Cannot Replace Tumor Marker Analysis in Bevacizumab-Based Cancer Therapy
Gastroenterology 2009, 136 (5), pp. A746-A746 Supp.1 Published:
IF 20.773
51. Schoppmann SF, Bareck E, Längle F, Zacherl J.
Gastrointestinal stromal tumors [Gastrointestinale Stromatumoren]
Journal für Gastroenterologische und Hepatologische Erkrankungen 2009, 7 (4), pp. 45-52.
52. Zacherl J, Schoppmann SF, Prager G, Lenglinger J, Eisler M, Cosentini EP, Miholic J, Riegler FM.
Endoscopic surgery for the treatment of achalasia [Endoskopische Chirurgie zur Behandlung der Achalasie]
Minimal Invasive Chirurgie 2008, 17 (4), pp. 205-208.
53. Gnant M, Schoppmann SF, Kuehrer I, Goetzinger P, Sahara K, Kandutsch S, Wrba F, Brostjan C, Goetzinger P, Turetschek K, Zielinski C, Teleky B, Friedl J, Stift A, Jakesz R.
Bevacizumab plus gemcitabine for the neoadjuvant treatment of locally advanced non-metastatic pancreatic cancer
Annals of Oncology 2008, 19, pp.70-71 Supp. 6
IF 13.930
54. Schima W, Schoppmann SF, Prager G.
Acute abdomen after laparoscopic cholecystectomy [Akutes abdomen nach laparoskopischer cholezystektomie]
Journal für Gastroenterologische und Hepatologische Erkrankungen 2007, 5 (3), p. 20.
55. Schoppmann SF, Jakesz R.
Early-stage breast cancer - Highlights at ASCO 2006
Breast Care 2006, 1 (4), pp. 265-269.
IF 2.028
56. Bachleitner-Hofmann T, Schoppmann SF, Rudas M, Birner P, Wiener H, Dubsy P, Blaha P, Sporn E, Panhofer P, Fitzal F, Roka S, Kandioler D, Gnant M, Jakesz R.
A case of phyllodes tumor with focal transition into low-grade lymphangiosarcoma
Breast Care 2006, 1 (6), pp. 391-394.
IF 2.028
57. Tamandl D, Gruenberger B, Herberger B, Schoppmann SF, Bodingbauer M, Fleischmann E, Schima W, Jakesz R, Laengle F, Gruenberger T.
Safe surgery for colorectal cancer liver metastases using modern dissection techniques
Annals of Oncology 2006, 17, pp. 57-57. Supp. 6
IF 13.930
58. Schoppmann SF, Fenzl A, Tamandl D, Bodingbauer M, Schindl M, Puhalla H, Gruenberger B, Teleky B, Gruenberger T, Längle F.
Impact of lymphangiogenesis in colorectal liver metastases
Annals of Oncology 2006, 17, pp: 33-33, Supp. 6
IF 13.930
59. Schoppmann SF.
Lymphangiogenesis, inflammation and metastasis
Anticancer Research 2005, 25 (6 C), pp. 4503-4511.
IF 1.865, cited 42 times

60. Schoppmann SF, Fenzl A, Laengle F.
Surgical oncology: Impact of lymphangiogenesis for metastasis formation
 European Surgery - Acta Chirurgica Austriaca 2005, 37 (3), pp. 153-158.
 IF 0.349, cited 3 times.
61. Schoppmann SF, Horvat R, Birner P.
Lymphatic vessels and lymphangiogenesis in female cancer: Mechanisms, clinical impact and possible implications for anti-lymphangiogenic therapies (Review)
 Oncology Reports 2002, 9 (3), pp. 455-460.
 IF 2.976, cited 80 times

3.3.3 Book chapters: Authorship and editorship

Schoppmann SF (ed.), Riegler M
Multidisciplinary Management of Gastroesophageal Reflux Disease
 Springer – Book 395065, in press

Chirurgie benignen Ösophaguserkrankungen (1. Auflage) Gockel (ed.)
Schoppmann SF: **Minimal-invasive Chirurgie gutartiger Tumoren des Ösophagus**
 Springer, in press

Schoppmann SF, Kristo I, Riegler M.
Innovations in minimally invasive therapy of GERD
 Surgery for Benign Oesophageal Disorders 2017, pp. 35-54.

Kristo I, Riegler M, Schoppmann SF.
Endoscopic therapy for barrett's esophagus: Who and how?
 Surgery for Benign Oesophageal Disorders 2017, pp. 105-132.

Devyatko E, Schoppmann SF, Zacherl J.
Resection of Benign Tumors
 Minimally Invasive Thoracic and Cardiac Surgery (ed. R. Inderbitzi)
 Book Chapter, pp. 329-339

Riegler M, Fischer See S, Schoppmann SF, Zacherl J.
Radiofrequency ablation and anti reflux management for non-dysplastic barrett's esophagus
 Innovation in Esophageal Surgery 2012, pp. 27-41.
 Book Chapter, cited 1 time.

Therapiemanagement Lebermetastasen bei Gastrointestinalen Tumoren
Schoppmann SF: **Lebermetastasen bei Magen – Ösophaguskarzinomen**
 Unimed Verlag AG, Bremen – London – Boston, 2008

4. TEACHING

Teaching				
Head of Clinical Teaching, MUV Task Force on Teaching				
Teaching documents in cancer surgery co-authored (Lehrunterlagen Block 13 Krebschirurgie; 2018)				
Courses (Evaluations Schoppmann Download)				
Semester	Type	No.	Title	Dauer (SSt)
Fall 2001	Tutorial	512.139	Tutorial in pathology/histology, 1	1
Fall 2001	Tutorial	512.140	Tutorial in pathology/histology, 2	3
Spring 2002 Fall 2005 Spring 2006	Tutorial	560.362	Tutorial in pathology/histology, 2	2 (6 total)
Spring 2002	Lecture	560.742	Tutorial in pathology/histology, 1	1
Spring 2004	Lecture	562.605	Molecular mechanisms of metastatization	2
Fall 2004 Fall 2005	SK	562.093	Issue-specific examination techniques, Term 5	1 (2 total)
Fall 2004 Fall 2005	SK	562.093	Issue-specific examination techniques, Term 5	1 (2 total)
Fall 2004	Lecture	562.605	Molecular mechanisms of metastatization	2
Fall 2005 Spring 2006 Fall 2009	Practicum	561.435	Intensive practicum: Surgery	8 (24 total)
Fall 2005	SK	653.539	Tertial 4 – Surgery 1 – 2E	8
Fall 2005	Lecture	901.641	Interdisciplinary breast cancer management	1
Fall 2005	Lecture	901.651	Neoangiogenesis in human tumors: Pathogenesis, clinical relevance, treatment options	
Fall 2005	Lecture	901.641	Interdisciplinary breast cancer management	1
Fall 2005	Lecture	901.651	Neoangiogenesis in human tumors: Pathogenesis, clinical relevance, treatment options	1
Spring 2006	SK	653.538	Tertial 4 – Surgery 1 – 4A	8
Spring 2007	SK	562.953	SSM3 – Project study (elective section)	4
Fall 2007 – Fall 2019	Seminar	901.846	Surgical management of gastrointestinal stromal tumors (GIST)	1 (25 total)
Fall 2007 – Fall 2019	Lecture	901.841	Angiogenesis and lymph angiogenesis in breast cancer	1 (25 total)
Fall 2007 – Fall 2019	Lecture	901.845	Molecular mechanisms in breast cancer	1 (25 total)
Fall 2007 – Fall 2019	Lecture	901.847	Inflammation and tumors: Clinical relevance	1 (25 total)
Fall 2007 – Fall 2019	Seminar	562.533	Interdisciplinary case reviews: Esophageal and gastric cancer (Oncoforum)	1 (25 total)

Spring 2008 – Fall 2019	Seminar	902.133	Surgical treatment concepts	2 (48 total)
Fall 2010	Practicum	731.101	Intensive practicum: Surgery	8
Spring 2011	SK	808.004	SSM 3 – Project study (elective section)	4
Fall 2014 Fall 2016 Fall 2017 Fall 2018 2019	Lecture Lecture	805.000	BL 13 – Nutrition and digestion BL 13 – Surgical Oncology	3 (12 total)

Supervision of degree, doctoral and habilitation candidates

Julia Dienes	Doctoral	Spring 2003
Gerd Jomrich	Degree	Fall 2006/2007
Lisa Roberts	Degree	Fall 2006/2007
Milena Nikolic	Degree	Spring 2017
Alexandra Fenzl	Doctoral	Fall 2004/2005
Ivan Kristo	Habilitation	2019
Katrin Schwameis	Habilitation	Submission in 2019

Memberships (select)

European Society of Surgical Oncology (ESSO)
American Foregut Society (AFS)
Austrian Society of Surgical Oncology (ACO-ASSO)
Austrian Society of Surgery (ÖGC)
Austrian Society of Robotic Surgery (ÖGR)
International Society for Diseases of the Esophagus (ISDE)
World Organization for Specialized Studies on Diseases of the Esophagus (OESO)

5. THIRD-PARTY FUNDING

Institution	Position	Project	Volume (€)
Funds acquired as Project Lead for FA731B0401, FA731B1801, KO27731012, KO731D0009, FA731B1802, UE73101036, UE73101006, JFÖNB 12072, rounded to nearest multiple of 10			
Hans and Blanca Moser Foundation	Lead	Lymph angiogenesis and lymphovascular invasion in liver metastasis of colorectal cancer	1,500
Austrian National Bank Jubilee Fund	Lead	Prediction of response to antiangiogenic tumor treatment (project no. 12072)	75,000
Novartis Pharma GmbH Austria	Lead	The RAF-1-MEK-ETV1 pathway and its clinical relevance in gastrointestinal stromal tumors	43,000
Pfizer Corp Austria GmbH	Lead	Clinically relevant gene screening in gastrointestinal stromal tumors by exome sequencing	75,270
Roche Austria GmbH	Lead	Evaluation of correlation of carbonic IX and Her-2 expression patterns in primary esophageal cancer and its lymph node and distant metastases	69,000
Dach Medical Group	Lead	Single-center observational study to evaluate the additional effect of posterior cruroplasty in patients treated with magnetic sphincter augmentation for gastroesophageal reflux disease	25,100
Pejcl Gerhard Medizintechnik	Lead	Temporary endoscopic implantation of a self-expanding stent in achalasia treatment (POETA I) - ID: NCT02518542	7,600
Janssen International	Lead	Unrestricted research grant to support research into the malignant disorders of the gastroesophageal	14,000
Covidien AG/Medtronic	Lead	Establishment of a MIC simulation course laparoscopic surgery (Animal-Lap)	95,500
Takeda Pharma GesmbH A/S	Lead	Prospective, non-randomized, observational study on the application of fibrin-supported fleece following lymph adenectomy in gastrectomy patients	12,800
Torax Medical Inc	Lead	Multicenter, prospective, observational study to evaluate the safety and efficacy of magnetic sphincter augmentation and fundoplication in patients with GERD	39,500
EndoStim Inc International	Lead	Prospective, open-label, non-randomized single-center study to evaluate the safety and efficacy of a new electric lower esophageal sphincter-stimulating device	153,600
Nycomed Pharma	Lead	Education Event	2,500
SRS Medigus	Co-Lead	Clinical evaluation of a novel, transoral, ultrasound-guided fundoplication device	61,000
Baxter	Lead	Laparoscopic suture and hemostatic techniques in the porcine model (semiannual), in collaboration with the MUV Center for Biomedical Research since 2016	65,700
AFS	Lead	Mesh support in hiatal hernia repair	39,500
Other unrestricted grants / course fees / surplus from events	Lead		19,500
Total (April 23, 2019)			800,070

